An investigational in vivo base editing medicine targeting ANGPTL3, VERVE-201, achieves potent and LDLR-independent liver editing in mouse models

27 August 2023 (10:25 - 10:35)
Organised by: Logo
Congress Presentation Part of: What's new in lipid lowering? Drug therapy ESC Professional Premium Access ESC Congress 2023 European Society of Cardiology

ESC 365 is supported by

ESC 365 is supported by